Abstract: Hybrid enclosures for power and optical fiber are provided herein. A hybrid enclosure includes a power conductor terminal and an optical fiber splice area that are in separate first and second trays, respectively. In some embodiments, the power conductor terminal is a terminal of a circuit that is configured to supply power exceeding 150 Watts. Enclosures including multiple protective lids over power conductor terminal blocks are also provided.

Abstract: A liquid pharmaceutical formulation comprising etoposide toniribate; a polysorbate; and ethanol. A method of preparing an infusion solution comprising diluting said liquid pharmaceutical formulation. Said composition or solution for use in treating cancer in a patient in need thereof.

Abstract: The invention relates to an improved composition for the control of parasites on animals, comprising comparably high amounts of active substances from the group of agonists of the nicotinergic acetylcholine receptors of insects (neonicotinoids) and from pyrethroids in a new and improved formulation comprising carvacrol as a solvent, and optionally additionally further active and/or auxiliary substances. In particular, the invention relates to the use of such compositions for the control of ectoparasites such as, in particular, fleas, ticks and sand flies in pets such as, in particular, in dogs and ferrets.

Abstract: The invention relates to an improved composition for the control of parasites on animals, comprising comparably high amounts of active substances from the group of agonists of the nicotinergic acetylcholine receptors of insects (neonicotinoids) and from pyrethroids in a new and improved formulation comprising carvacrol as a solvent, and optionally additionally further active and/or auxiliary substances. In particular, the invention relates to the use of such compositions for the control of ectoparasites such as, in particular, fleas, ticks and sand flies in pets such as, in particular, in dogs and ferrets.

Abstract: The invention relates to an improved composition for the control of parasites on animals, comprising comparably high amounts of active substances from the group of agonists of the nicotinergic acetylcholine receptors of insects (neonicotinoids) and from pyrethroids in a new and improved formulation comprising an aliphatic cyclic carbonate, an aromatic alcohol, sorbitan monolaurate (Span 20) and optionally additionally further active and/or auxiliary substances. In particular, the invention relates to the use of such compositions for the control of ectoparasites such as, in particular, lice, fleas, ticks, mosquitoes and sand flies in pets such as, in particular, in dogs and ferrets.

Abstract: The invention relates to an improved composition for the control of parasites on animals, comprising comparably high amounts of active substances from the group of agonists of the nicotinergic acetylcholine receptors of insects (neonicotinoids) and from pyrethroids in a new and improved formulation comprising an aliphatic cyclic carbonate, an aromatic alcohol, sorbitan monolaurate (Span 20) and optionally additionally further active and/or auxiliary substances. In particular, the invention relates to the use of such compositions for the control of ectoparasites such as, in particular, lice, fleas, ticks, mosquitoes and sand flies in pets such as, in particular, in dogs and ferrets.

Abstract: A method for converting UO3 and/or U3O8 into hydrated UO4 of formula UO4.nH2O wherein n is 2 or 4, comprising the following successive steps: a) preparing an aqueous suspension of a UO3 powder and/or a U3O8 powder; b) adding hydrogen peroxide H2O2 to the aqueous suspension of a UO3 and/or U3O8 powder, converting the UO3 and/or U3O8 into hydrated UO4 and precipitating, crystallizing the hydrated UO4 in the suspension; c) recovering the precipitate, crystals of UO4 hydrate; d) optionally, washing the recovered UO4 hydrate precipitate, crystal(s); e) optionally, repeating step d); f) optionally, drying the precipitate, the crystals; wherein the addition of H2O2 to the aqueous suspension is carried out so that the suspension contains a stoichiometric excess of H2O2 relatively to the stoichiometry of the reaction from UO3: UO3+nH2O+H2O2?UO4.nH2O+H2O??(1) or of the reaction from U3O8 UO2.67+1.33H2O2+nH2O?UO4.nH2O+1.

Abstract: A method for converting UO3 and/or U3O8 into hydrated UO4 of formula UO4.nH2O wherein n is 2 or 4, comprising the following successive steps: a) preparing an aqueous suspension of a UO3 powder and/or a U3O8 powder; b) adding hydrogen peroxide H2O2 to the aqueous suspension of a UO3 and/or U3O8 powder, converting the UO3 and/or U3O8 into hydrated UO4 and precipitating, crystallizing the hydrated UO4 in the suspension; g) recovering the precipitate, crystals of UO4 hydrate; h) optionally, washing the recovered UO4 hydrate precipitate, crystal(s); i) optionally, repeating step d); j) optionally, drying the precipitate, the crystals; wherein the addition of H2O2 to the aqueous suspension is carried out so that the suspension contains a stoichiometric excess of H2O2 relatively to the stoichiometry of the reaction from UO3: UO3+nH2O+H2O2?UO4.nH2O+H2O??(1) or of the reaction from U3O8 UO2.67+1.33H2O2+nH2O?UO4.

Abstract: The present invention relates to a flupirtine-containing lyophilisate, the use of this lyophilisate to produce a pharmaceutical composition to be parenterally applied, a procedure to produce a flupirtine-containing pharmaceutical composition to be parenterally applied, and a procedure to produce the flupirtine-containing lyophilisate as well as the flupirtine-containing pharmaceutical composition produced using the lyophilisate. For this purpose a lyophilisate is provided which contains the active ingredient flupirtine in the form of a physiologically tolerated salt, which has a solubility in water of at least 2.5 mg/ml, preferably at least 5 mg/ml, especially preferably at least 10 mg/ml, and contains one or more cyclodextrins or cyclodextrin derivatives, and which may be used to produce a pharmaceutical composition to be parenterally applied.

Abstract: A lyophilisate having as an active ingredient flupirtine in base form or as a physiologically tolerated salt is suitable for producing a pharmaceutical composition for parenteral administration. The physiologically tolerated salt is an acid addition salt of flupirtine. The lyophilisate contains at least one additive selected from the group consisting of a cake-forming agent, an antioxidant, and a detergent. In a process for producing a flupirtine-containing pharmaceutical composition for parenteral administration, a flupirtine-containing lyophilisate is dissolved in at least one solvent that is an aqueous medium or an organic solvent or a combination thereof to obtain a liquid pharmaceutical composition ready for use. In a process for producing a flupirtine-containing lyophilisate, a flupirtine solution is prepared by dissolving flupirtine base in an aqueous medium and the flupirtine solution is freeze dried.

Abstract: An acceleration-sensitive device, particularly a seat belt retractor locking device responsive to vehicle acceleration, comprising a rollable, fully movable inertia member supported in a depression provided in a support member, and an actuator means disposed above the inertia member and engageable with a locking means provided in said device, the actuator means being provided with a depression facing the inertia member, the improvement comprising the depression on the support member and the depression on the actuator means being in the form of a ring facing towards the inertia member, the inertia member having an approximately spherical shape, and the support member extending laterally outside its ring in an upwards direction so as to at least partially surround the inertia member.

Abstract: 1. Immunological method for the determination of free substances having hapten properties.2.1. Immunological methods for the determination of free substances having hapten properties, especially of free thyroid hormones, are based on various determination principles, all of which either have disadvantages from the practical viewpoint or, by reason of the basic principle of the method, provide limited information in marginal cases. The new method is intended to simplify and improve the routine clinical determination of free substances, because of the avoidance of sources of error associated with known methods, while having a procedure which is straightforward for practical use.2.2.